Effects of (pre-) analytical variables on activated protein C resistance determined via a thrombin generation-based assay by Rosendaal, F.R.
Θ 2002 Sthattauci GmbH Stuttgart Thromb Haemost 2002 87 483-92
Effects of (Pre-)analytical Variables on Activated Protein C
Resistance Determined Via a Thrombin Generation-based
Assay >
Joyce Curvers1, M. Christella L. G. D. Thomassen1, Hans de Ronde2,
Rogier M. Bertina2, Frits R. Rosendaal3, Guido Tans1, Jan Rosing1
1 Department of Biochemistry, Cardlovascular Research Institute Maastricht, Maastricht University, Maastricht
The Netherlands and the 2Hemostasis and Thrombosis Research Center and 3the Department of Clmical
Epidemiology, Leiden University Medical Center, The Netherlands
Keywords
APC Resistance, Factor VLeiden
Summary
The normahzed activated protem C sensitivity ratio (nAPC-sr)
determmed with an assay that quantifies the effect of APC on throrabm
formation mitiated via the extnnsic coagulation pathway identifies
hereditary and acquired defects of the protem C systera We
investigated the mfluence of assay conditions (analytical variables) and
plasma handlmg (pre-analytical variables) on nAPC sr obtamed with
this APC resistance test The effect of the analytical variables (CaCl2,
phospholipid and APC concentrations and the concentration and source
of tissue factor) was determmed m pooled normal plasma Inhibition of
thrombin formation by APC was dependent on the APC concentration
and was also affected by the tissue factor, Ca2+ and phospholipid
concentrations Thus, stnct standaidization of reactant concentrations is
required to obtam reproducible nAPC sr Three diffeient tissue factoi
preparations were compared by determmmg nAPCsr m plasma samples
obtamed from 90 healthy mdividuals nAPC sr were similar for all
three tissue factor preparations although, compared with the non-
commercially available tissue factor used m earlier studies, values
determmed with commercial tissue factor preparations showed larger
Variation Pre-analytical variables, investigated in plasma of mne
volunteers (3 normal mdividuals and 6 mdividuals with an APC-
resistant phenotype) were concentration of anticoagulant (3 2% vs
3 8% tnsodiumcitrate), time before processmg of blood (0, 4 and
24 h), centnfugation speed, storage temperature of plasma (-20° C vs
-80° C) and sample thawmg Multiple linear regression analysis
showed that only the citrate concentration affected the nAPC-sr, which
was higher m samples collected in 3 2% tnsodiumcitrate than m
samples collected m 3 8% tnsodiumcitrate
Introduction
The Identification of the A1691G mutation m the factor V gene
(l 4), resultmg m a mutated factor V molecule (factor VUlden, factor
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VR506Q), has led to a higher number of patients with an identifiable
prothrombotic disorder Arg506 represents a predommant target for
proteolytic mactivation of factor Va by activated protem C (APC) and
äs a result of the Arg506-Gln mutation factor VaUlden is more resistant to
APC ( 1 , 5 7 ) Moreover, it appears that the mutation m factor VLcidcn
also results in a substantial loss of the cofactor activity of factor V in
APC dependent down regulation of factor VIII(a) (8, 9) APC
resistance, which is found m 20% of patients with venous thrombosis
(10, 11), also occurs m mdividuals without factor VLeiden and
recently it was shown that APC resistance m the absence of the factor
^Leiden mutation is Ά nsk factor for venous thrombosis (12 14) APC
resistance without factor VLcidcn can be attnbuted to other hereditary
defects of the protem C palhway or to acquired coagulation
abnormahties occumng dunng oral contraceptive (OC) use or pregnancy
(1518)
In 1997 we developed an assay (17, 19) in which the anticoagulant
effect ot APC m plasma is quantified by measurmg the effect of APC
on thrombin geneiation miliated via the extnnsic coagulation pathway
This assay not only allows detection of the factor VLciil(;il mutation,
but is also sensitive for acquired APC resistance occurrmg dunng OC
use (17, 20, 21) In contrast, the classical aPTT based APC resistance
test is much less affected by OC use (20)
Smce APC sensitivity ratios (APCsr) determmed with the thrombin
generation-based assay change m parallel with thrombotic risks
reported m epidemiological studies (22), this assay may gam mterest of
other research or coagulation laboratones In this paper we report how
the quantification of APC resistance with the thrombin generation
based test is affected by analytical variables i e the APC, Ca++ lons and
phospholipid concentrations, and the source and concentration of tissue
factor and by pre-analytical variables i e blood collection and handlmg
and storage of plasma
Materials and Methods
Materials
Tns (Tns (hydroxymethyl ammo methane), Hepes (N-(2 Hydroxyethyl)
piperazme N' (2 ethanesulfomc acid), NaCl, EDTA (Ethylenedimtnlo
tetraacetic acid), BSA (bovme serum albumm) and ovalbumm were purchased
from Sigma, St Louis, USA The chromogemc Substrates D-Phe (pipecolyl)
Arg pNA (S2238) and L-pyroGlu-Pro Arg-pNA (S2366) were supplied by
Chromogemx, Molndal, Sweden Ancrod, obtamed from the WHO
International Laboratory for Biological Standards (NIBSC, Hertfortshire,
England) was dissolved in distilled water (50 U/ml) and stored at -20° C
1,2 Dioleoyl-sn glycero-3 phosphosenne (DOPS), l 2 dioleoyl-4« glycero
3 phosphochohne (DOPC) and l 2 dioleoyl sn glycero 3 phosphoethanolamme
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Variation of pre-analytical conditions
anticoagulant
concentration
tlmebefore centrifugation storage sample
processing procedure temp thawlng
Fig l Schematic diagram of different
procedures of plasma preparation and storage
(DOPE) were obtamed from Avanti Polar Lipids, Alabaster, Alabama, USA
Small umlamellar phosphohpid vesicles composed of DOPS/DOPE/DOPC
(20/20/60, M/M/M) were prepared by mixmg appropnate quantities of
phosphohpid dissolved m CHC13/CH,OH (9/1 v/v) m a glass tube The
phosphohpids were dned under a mild flow of N2 and stored at -20° C Before
use the dned phosphohpids were brought to room temperature, suspended m
25 mM Hepes (pH 7 5) 175 mM NaCl by ngorous vortexmg for at least
l min and subsequently somcated for 10 mm at 4° C with a MSE
Somprep 150 ultrasonic dismtegrator set at 7 5 μιη peak to peak amphtude
Phosphohpid concentrations were determmed by phosphate analysis (23)
Punfied human APC was from Enzyme Research Laboratories (ERL) and
supphed by Kordia Laboratory Supphes, Leiden, The Netherlands APC was
diluted m 25 mM Hepes (pH 7 5 at 37° C), 175 mM NaCl, 5 mg/ml BSA and
frozen m small portions at -80° C APC concentrations were determmed with
S2366 usmg kmetic parameters reported by Sala et al (24)
Recomboplastm S without additives was a kmd gift of Dr H Pelzer (Dade,
USA) Rehpidated recombmant tissue factor Dade Innovm® was purchased
from Behrmg RecombiPlasTm0 (Ortho) was from Instrumentation
Laboratories Tissue factor preparations were reconstituted accordmg to the
mstructions of the manufacturer In Standard coagulation assays tissue factor is
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added m excess and can be used for several days when kept at 2-8° C followmg
reconstitution In the thrombin generation based APC resistance assay tissue
factor is used m high dilutions (see below and Results) and to improve day
to day reproducibihty reconstituted tissue factor preparations were stored m
small ahquots at -80° C Tissue factor concentrations were determmed with an
antigen assay (American Diagnostics)
Plasma Preparation for Investigatmg the Effecl ofAnalytical Variables on the
Blood was obtamed by clean vempuncture m the forearm, without pressure
and discardmg the first 2 ml of blood Nme parts of biood were collected m one
part of 0 13 M (3 8%) tnsodium citrate (pH 7 8) and the blood was centnfuged
for 15 mm at 3000 X g at room temperature, followed by centrifugation for
30 mm at 20,000 X g at 4° C (17, 20) The cell free plasma was stored at
-80° C until analysis A pooled normal plasma was prepared from plasma
of healthy volunteers not on medication, not usmg OC and non pregnant
(21 females and 44 males, mean age 35 years) The mdividuals who donated
blood for pooled normal plasma were not screened for factor VUl(len or other
hereditary coagulation abnormahties
Cui vers et al APC Resistance Test
Plasma Preparahonfor Investigatmg the Effect ofPre analytical Variables
on the nAPCsr
Blood was collected from nme volunteers three factor V^,, negative
mdividuals (2 men, 47 and 55 years,,! woman, 51 yr), three heterozygous
factor VUldal carriers (l man, 30 yr, l Wöman, 41 yr and a 32 yr old woman who
was l month pregnant) and three women (<30 years of age) ustng a mono-
phasic oral contraceptive (OC) preparation contammg 30 μg ethmyl estradiol
and 150 μg desogestrel The presence of the factor V^^ mutation was
estabhshed by DNA analysis (25)
The handlmg of the blood samples and the preparation and handlmg of
plasma samples from the volunteers is schematically presented in Fig l Nme
parts of blood were collected m one part of 3 2% (0 109 M) or 3 8% (0 130 M)
tnsodium citrate and divided into three equal portions, one part of which was
immediately further processed and the others were left 4 or 24 h at
room temperature before processing Platelet poor plasma was obtamed by
centnfugmg either 15 mm at 2000 X g at room temperature or 15 mm
at 3000 X g at room temperature followed by 30 mm at 20,000 X g at 4° C
Samples were frozen m small ahquots and stored at either -20° C or -80° C
until analysis For each variable one aliquot was thawed once and refrozen
agam Taken together this resulted m 432 samples (9 mdividuals X 48 combi
nations) available for analysis The nAPCsr of all 48 samples belongmg to an
individual were determmed m the same Session The nAPC sr m six samples
was not determmed because the plasma was clotted upon thawmg and 27
samples were left out of analysis because m these measurements residual
thrombin formation determmed in the presence of APC m normal plasma feil
outside the ränge 6-16% (see also Results section)
APC resistance Assay and Determination ofthe nAPCsr
Plasmas were thawed and defibrmated with Ancrod (l U/ml final
concentration) for 10 mm at 37° C after which the clot was removed with a
plastic spatula (Sarstedt) Defibrmated plasma was used withm 3 h after
defibrmation The APC resistance assay was routmely pertormed äs descnbed
before (17, 20) Bnefly, 80 μΐ defibrmated plasma was mcubated at 37° C and
thrombin formation was imtiated with 45 μΐ startmg solution (prewarmed at
37° C) contammg tissue factor, CaCl2, phosphohpid vesicles with or without
APC m 25 mM Hepes (pH 7 5 at 37° C), 175 mM NaCl, 5 mg/ml BSA
This resulted in final concentrations of 0 4 ng/ml tissue factor 16 mM added
CaCl2, 15 μΜ phosphohpid vesicles (DOPS/DOPC/DOPE, 20/60/20, M/M/M)
and if present, 5 nM APC Smce commercial tissue factor preparations, after
reconstitution accordmg the manufacturers mstructions, usually contam
between 300 and 400 ng/ml tissue factor the final tissue factor concentration m
the assay mixtures corresponds to an approximate 900-fold final dilution of
reconstituted tissue factor preparations It should be noted that m earlier
publications (17,19, 20) the tissue factor concentration was abusively given äs
0 l ng/ml When quantified with an antigen assay (American Diagnostics) the
tissue faUor concentration used m the previous studies was 0 4 ng/ml
After 20 mm an aliquot from the plasma mixture was diluted 50-fold in a
50 mM Tris buffer (pH 7 5 at 37° C) contammg 175 mM NaCl, 20 mM EDTA
and 0 5 mg/ml ovalbumm The amount of Alpha2-Macroglobulm thrombin
(ajM-IIa) complex present m the diluted plasma mixture, which is a measure
for the amount of thrombin generated (19, 26), was quantified by addmg an
appropnate aliquot from the diluted plasma (100 μΐ without APC, 200 μΐ with
APC) to the well of a microtiterplate contammg buffer with S2238 The well
fmally contamed 250 μΐ 50 mM Tris (pH 7 5 at 37° C), 175 mM NaCl,
0 5 mg/ml ovalbumm, 20 mM EDTA and 235 μΜ S2238 The rate of change m
absorbance was determmed at 405 minus 492 nm at 37° C m a 340 ATTC
microtiterplate reader (SLT Labinstruments, Salzburg, Austna) set m the
kmetic mode The amidolytic activity was corrected by blank values measured
m plasma samples (80 μΐ) to which 45 μΐ 25 mM Hepes (pH 7 5 at 37° C),
175 mM NaCl, 5 mg/ml BSA with or without APC was added and which were
subjected to the same mcubation and dilution procedure äs descnbed above
In routme nAPC sr determmations 21 subject plasmas together with 3 samples
of pooled normal plasma (first, middle and last sample) were determmed m
duplicate to yield a total of 96 amidolytic measurements on a smgle micro-
titerplate (48 with and 48 without APC) From the a2M-lla amidolytic activities
(± APC) thus obtamed m subject plasma and m pooled normal plasma determmed
m the same microtiterplate the nAPC sr was calculated äs
nAPC-sr =
(a2M-IIa+Apc/a2M-IIa APc)plasmasample
/(a2M-IIa+APC/ol2M IIa APc)pooled normal plasma
Staüsücs
The mfluence of Variation of pre-analytical variables on the nAPCsr of the
plasma samples ofthe nme individual volunteers (see also above) was assessed
m a multiple linear regression model with nAPC-sr äs dependent variable usmg
mdicator variables for the nme mdividuals In the companson of different tissue
factor preparations differences of means and 95% confidence mtervals were
calculated m the Standard fashion
Results
Effects of Tissue Factor, CaCl2 and Phosphohpid Concentrations on
Thrombin Generation m the Absence and Presence ofAPC
For quantification of the effect of APC on thrombin formation tt is
not necessary to measure complete ttme courses of thrombin generaüon
Thrombin generaüon curves typically reach a residual level of amidolytic
activity that can be attnbuted to the ct2M IIa complex (27,28) The «2M
IIa level rematns constant m time and is a direct mdicator for the amount
of thrombin generated m plasmas with the same a2M levels (19, 26)
Smce this is particularly the case when the same plasma is tested with
and without an effector of thrombin generation, the effect of reactants
e g APC on thrombin generation can simply be quantified on the basis
of smgle amidolytic assays of the end levels of a2M-IIa present m plasma
m which thrombin was generated m the absence and presence of APC
Fig 2 shows the results of titration expenments m which the
concentration of one of the teactants (tissue factor, CaCl2 or phospho-
hpid) was vaned while the others were kept constant at concentrations
at which the routme assay is performed (see below) In the absence of
APC (open Symbols) optimal thrombin formation was observed at
04 ng/ml tissue factor (Fig 2A), 16 mM added CaCl2 (Fig 2B) and
2 5 μΜ phosphohpid vesicles m addition to the lipid present m the
rehpidated tissue factor preparation (Fig 2C)
In the presence of 5 nM APC thrombin formation was mhibited at all
reaction conditions tested (Figs 2 A-C, closed symbols) However,
with 5 nM APC thrombin formation increased at increasing tissue
factor and CaCl2 concentrations This mdicates that the efficacy by
which APC mhibited thrombin formation gradually decreased at higher
tissue factor (Fig 2A) and CaCl2 concentrations (Fig 2B) In the
presence of APC, thrombin formation progressively decreased when
the amount of phosphohpid m the assay was increased, mdicatmg that
the ability of APC to inhibit thrombin formation was enhanced at
higher phosphohpid concentrations (Fig 2C, closed symbols)
Based on these data routme assay conditions (15 μΜ phosphohpid,
04 ng/ml tissue factor and 16 mM CaCl2) were chosen such that
thrombin formation m the absence of APC was insensitive to small
vanations m concentrations of phosphohpid, tissue factor or CaCl2 (see
also Discussion)
Effect ofAPC on Thrombin Formation m Normal Plasma and m
Factor VUlden Plasma
The expenment presented m Fig 3 shows the effect of increasing
APC concentrations on thrombin generation m pooled normal plasma
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Fig. 2 Effects of varying amounts of tissue factor, Ca2+ ions and phospholipid on thrombin generation in pooled normal plasma. Thrombin formation was
mitiated m defibnnated pooled normal plasma with a mixture contaming varying amounts of: A) tissue factor (DADE® Innovin®), B) Ca2+-ions or C) phospholipid
vesicles while keeping the others constant al 0.4 ng/ml tissue factor, 16 mM Ca2+ ions and 15 μΜ phospholipid either without (O) or with (·) 5 nM APC (final
concentrations in the assay mixlure). Thrombin formation is expressed in arbitrary units (final levels of a2M-IIa complex present in plasma after 20 min). Y-error
bars indicate the 95% confidence mterval (n = 4). Some error bars are not visible since their size was less than that of the markers indicating the data points
and in plasmas from a normal male volunteer and from a male
heterozygous carrier of factor VUlden. In all plasmas residual thrombin
formation (expressed äs percentage of thrombin formation determined
in the absence of APC) gradually decreased at increasing APC
concentrations. However, thrombin formation in the plasma from the
heterozygous carrier of factor VLciden was less sensitive to APC than
that in plasma from the wildtype volunteer which at all APC
concentrations tested showed a sensitivity towards APC similar to that
of pooled normal plasma.
Quantification ofthe Effect ofAPC on Thrombin Generation
In APC resistance tests the sensitivity of a particular plasma for APC
is commonly determined on the basis of an APC sensitivity ratio
(APCsr) which is defmed äs the ratio ofthe test result with and without
APC. In the thrombin generation-based APC resistance test:
APCsr = (a2M-IIa+APC/a2M-IIa APC)
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The nAPCsr was introduced (25) to minimize day-to-day Variation
and is calculated by dividing the APCsr of a plasma sample by
the APCsr of pooled normal plasma determined in the same experiment
i.e.
nAPC-sr = APCsr,plasma samp pooled normal plasma
During the development of the thrombin generation-based APC
resistance test the concentration of APC added to plasma was chosen
such that residual thrombin generation in the presence of APC was 10%
(19). However, due to small variations in reaction conditions, residual
thrombin formation in normal pooled plasma may deviate from 10%.
This has different effects on the APCsr and the nAPCsr of a particular
plasma sample. Fig. 4 compares the APCsr and the nAPC-sr of plasma
from the wild type volunteer (Fig. 4A) and from the heterozygous
carrier of factor VLeiden (Fig. 4B) when residual thrombin formation in
pooled normal plasma varied between l % and 18% (data from Fig. 3).
The APCsr of the wildtype volunteer showed a 20-fold increase at
JlVOjflUjfllpr



















Fig 3 Effects of varymg amounts of APC on residual thrombin formation m
pooled normal plasma plasma from a healthy man and factor VL,, äm plasma
Thrombm formation was imtiated in defibrmated plasma at 0 4 ng/ml tissue
factor (Innovm) 16 mM Ca++ lons and 15 μΜ phospholipid vesicles and
amounts of APC äs mdicated in the figure Thiombm formation m the presence
of APC was expressed äs percentage of thrombin formation deternnned in
the absence of APC for (O) pooled normal plasma (Δ) plasma of a male
volunteer, (·) plasma of a heterozygous carrier of factor V^^, Y-error bars
mdicate the 95% confidence mterval (n = 4)
increasmg levels of residual thrombin formation m pooled normal
plasma, whtle the nAPC-sr remamed virtually constant when residual
thrombin formation m the pooled normal plasma vaned between 5%
and 18% (Fig 4A) In the plasma from the factor VLeidt|1 cainer an
opposite ttend was observed The nAPC sr of factor VLeidtn plasma
strongly depended on the percentage of tesidual thrombin formation in
pooled normal plasma When this was less man 5% the nAPC-sr of the
factoi VLclden plasma became very high with large enor margms
(Fig 4B) The APCsi (not normalized) of factoi VUldcn plasma was
much less affected under these conditions At levels of residual
thrombin formation m normal plasma above 5% the APCsr and the
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Fi? 4 Companson of APCsr and nAPC sr APC si (A) and nAPC sr (·)
determmed m plasma fiom the healthy volunteer (A) and the carrier of factor
Vu den (B) were calculated tiom the data presented in Fig 3 äs descnbed m the
Results section The APC sr (X 10 to enable direct companson with the
nAPC sr) and the nAPC sr are plotted äs function of residual thrombin
formation m pooled normal plasma Υ error bars mdicate the 95% confidence
mterval (n = 4)
Table l Between assay Variation of the




Healthy mdividual without factor V^
APCsr (x 10) 180
nAPCsr 179
Factor Vi^den plasma






The APCsr (x 10 to enable direct companson with the nAPCsr) and nAPCsr were
determmed on 18 different days m pooled normal plasma, plasma from an mdividual with
mild phenotypic APC resistance and plasma from a heterozygous carner of factor Vi^den For
futher details see text and Materials and Methode
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With all tissue factor preparations a significant difference between the nAPCsr of men and
women was observed (p <0.001). For further details see text and Materials and Methods.
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Fig 5 Correlations between nAPC-sr determmed with different tissue factor preparations Correlation plot of the nAPC-sr determmed with (A) Innovin and
Recomboplastin S, (B) RecombiPlasTin and Recomboplastin S and (C) Innovin and RecombiPlasTin
Curvers et al APC Resistance Test
Table 3 Effects of pre-analytical variables on
the nAPCsr
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132 099-166 134 096-172
269 156-382 292 144-441
441 354-528 406 333-479



























Mean nAPC-sr values and 95% C I were calculated for mdividuals with a sirmlar
genotype/phenotype GG = normal genotype, AG = factor VLeldeo heterozygous genotype, OC
= oral contraceptives * refers to the routmely used plasma preparation procedure
Table l summanzes the between assay Variation of the (n)APCsr
obtamed by determimng the effect of 5 nM APC on thrombm formation
in pooled normal plasma, plasma from a healthy volunteer with an
mtermediate APCsr and a factor VLci(]Ln plasma on 18 different days
The average residual thrombin formation m the normal plasma was
10 1% (ränge 65 138%) with a coefficient of Variation (%CV ι έ
SD/meanX 100%) of 20 8% The%CVofthe(n)APCsrdetermmedm
plasma fiom the healthy normal volunteer were 14 8% (nAPCsr) and
23 1% (APCsr) Also m the case of factor VLei(ieil plasma, the %CV of
the nAPCsr (12 4%) was lower than that of the APCsr (17 5%)
Comparison of Different Tissue Factor Preparatwns
In earher studies concernmg the thrombin generation-based APC
resistance lest (17, 19 21) a tissue factor preparation was used that
is not commercially available To compare this preparation with
commercial tissue factor preparations, we determmed the nAPC-sr of
90 plasmas from normal healthy mdividuals (52 men, 38 women) usmg
our earher preparation (Recomboplastin S) and two commercially
available tissue factors (Dade® Innovm® and Ortho RecombiPlasTm®)
at 0 4 ng/ml tissue factor, 16 mM CaCl2 and 15 μΜ added phosphoh
pid vesicles The results obtamed are summanzed m Table 2 APC
concentrations needed to attam 10% residual thrombin formation m
pooled normal plasma were 4 8 nM APC for Innovm®, 5 2 nM APC for
RecombiPlasTm® and 5 0 nM APC for our original tissue factor
preparation (Recomboplastin S), which hmts at small differences
between the preparations Average nAPC-sr obtamed were, however,
not statistically different for all tissue factor preparations Plasma from
women was more resistant to APC than plasma from men (Table 2)
An excellent correlation was observed between the original non
commercial recomboplastm S and Innovm® (r = 0 92, Fig 5A) and a
somewhat lower correlation with RecombiPlasTm® (r = 0 79, Fig 5B)
However, due to a relative lack of low nAPC-sr values m the
determmation with the original recomboplastm S preparation,
regression hnes did not cross the ongm The two commercially
available tissue factor preparations showed a good correlation (r = 0 71)
with a regression Ime which passes through the ongin and which has a
slope of 0 94 mdicatmg that nAPC-sr values showed sirmlar mdividual
Variation with these preparations (Fig 5C)
Effect of Plasma Handhng on the nAPC sr ofNme Individual Plasmas
To obtam Information on the mfluence of plasma handlmg (i e
pre-analytical variables) on the nAPC-sr, plasmas from mne mdividual
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Variables 95% CI
3.2% «träte vs 3.8% citrate M
4 hrs delay vs immediate processmg
24 hrs delay vs immediate processmg
stngle vs double centnfugation
storage at -20°C vs -80°C













nAPC-sr were obtamed m plasmas of nme mdividuals processed by 48 different methods and
analyzed in a multiple regression model. The nme mdividuals were mcluded äs mdicator
variables and the effect of a change in preanalytical vanable was assessed agamst the routme
method of plasma preparation (3 8% citrate äs anticoagulant, immediate processmg of the
blood sample, double centnfugation, storage at -80°C and no extra thawmg)
Table 4 Regression model for the thrombin
generation-based nAPC-sr
volunteers with a large Variation in the nAPC-sr were collected and
subjected to different treatments äs descnbed under Materials and
Methods (cf Fig 1) The pooled normal plasma used for normahzation
of the nAPCsr was collected accordmg to the Standard procedure (nme
parts of blood m one part 3 8% citrate) and processed äs descnbed m
Materials and Methods
The results are summanzed m Table 3 Under all circumstances
the plasma sample from the heterozygous carner of factor VLcldcn,
who was l month pregnant, had the highest nAPC-sr The nAPC sr
determmed for the heterozygous factor VLcidcn carners showed values
comparable to the women who did not carry the factor VLu(kn mutation
but who were usmg oral contraceptives Values close to normal plasnu
were obseived for the non-factor VUldcn men and for the non-factor
VUldeil woman who was not usmg oral contraceptives (Table 3)
These nAPC-sr are m agreement with earher leported values (17, 20)
The data obtamed for all possible combmations of plasma
processmg were analyzed m a multiple regression model which
mcluded the nme mdividuals äs mdicator variables (Table 4) Thereby,
adjustment for mdividual differences (factor VUlden carners, OC users
and pregnant woman) was achieved The model showed that the citrate
concentration and the 24 h wait at room temperature before the
blood was processed were variables that clearly mfluenced the
nAPC-sr measurement (Table 4) The largest effect was observed with
the anticoagulant concentration Samples collected on 3 2% citrate
showed an average mcrease of 0 74 of the nAPCsr compared to plasma
collected on 3 8% citrate The difference between the nAPCsr of plasma
collected on 3 2% and 3 8% citrate became less m samples with higher
nAPC-sr (Table 3) The other pre-analytical vanations i e centnfugation
procedure, 4 h wait at room temperature before processmg of the blood
sample, temperature dunng 3-month storage äs well äs additional
sample thawmg did not notably mfluence the nAPC-sr (Table 4)
Discussion
The data reported here concern the effects of vanations m plasma
handlmg and assay conditions on nAPC-sr values determmed with the
thrombin generation-based APC resistance test descnbed m earher
pubhcations (17, 19, 20) It has been reported that the measurement of
the nAPC-sr with this assay, apart from allowmg detection of the factor
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^Leiden mutation, is very sensitive foi conditions of acquired APC-
resistance such äs it occurs dunng the use of oial contraceptives (17,
20, 21) and pregnancy (29-31) Part of this sensitivity is likely due to
the decision to use an APC concentration which dimmishes thrombin
formation in normal plasma by 90% This results m a large wmdow for
the nAPC-sr (values between l and 10) of APC resistant samples How-
ever, m order to obtam results that are comparable from study to study
and between different laboratones the assay conditions need to be
standardized The assay conditions were chosen such that thrombin
formation m the absence of APC is insensitive to small vanations m the
phosphohpid, CaCl2 or tissue factoi concentrations The amount of
phosphohpid present m the assay mixture (15 μΜ) is higher than the
concentration required for optimal thrombin tormation m the absence
ot APC The use of a high phosphohpid concentration makes the assay
insensitive to small amounts of phosphohpid present m plasma and
also limits the amount of APC required to mhibit thrombin formation
However, measurements obtamed in the presence of APC and thus, the
nAPC-sr remam sensitive to vanations m concentrations of reactants
(cf Figs 2-4) and therefore, standardization is essential m order to
mmimize withm- and between laboratory Variation
It is not surpnsmg that the ability of APC to mhibit thrombin
formation is decreased at higher tissue factor and CaCl2 concentrations
and mcreases when the amount of phosphohpid present m the assay
mixture is mcreased At high tissue factor concentrations excessive
amounts of factor Xa and factor Va will be formed, which will result m
a condition at which APC is mcapable to effectively mactivate factor
Va and mhibit thrombin generation The observation that m model
Systems contammg punfied protems APC-catalyzed factor Va mactiva-
tion has a sharp Ca2+ Optimum (3 mM) and is mhibited at high Ca2+
concentrations (32), can explam the mcrease of residual thrombin
formation at mcreasmg amounts of Ca2+ The fact that APC has a rather
low affimty for negatively charged phosphohpids (33) can account for
the mcreased effectivity by which APC down-regulates thrombin
formation at higher phosphohpid concentrations
In order to obtam reproducible nAPC-sr, it is necessary to ensure
that the residual thrombin formation determmed m the presence of APC
m normal plasma is close to 10% (Fig 4) A good day-to-day repro-
ducibihty is then achieved, which can be further improved by
normalizmg agamst the APC-sr obtamed m pooled normal plasma m
l
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the same run When the level of residual thrombin formation m pooled
normal plasma is kept withm a narrow ränge (6 16%) the coefficients
of Variation of the n APC sr(SD/mean X 100%) were 148% and 124%
for plasma of a healthy donor and a heterozygous factor VUlden camer,
respectively (Table 1)
When residual thrombin formation m pooled normal plasma is
below 6%, normahzation ιέ dividmg the percentage of residual
thrombin formation m the plasma sample by that determmed m pooled
normal plasma leads to systematic overestimation of nAPC-sr m APC
resistant samples and the mter- and mtra-assay vanabihty becomes too
large (Fig 4) The extent of overestimation of the APCsr is then
reduced by omittmg the normahzation procedure There is a second
reason why normahzation may affect the actual value of the nAPCsr
determmed for an individual plasma sample The presence of äs low äs
2 5% factor V^,^,, carner plasma already affects the APCsr of the
pooled normal plasma (34) Thus, normahzation agamst a normal
plasma m which users of oral contraceptives or camers of factor VUlden
are included in the subjects who donate blood will result m lower
nAPC-sr for individual plasma samples than nAPCsr normahzed
agamst a pooled normal plasma from which users of oral contraceptives
and cameis ot factor VLciden are excluded In order to allow companson
of nAPC-sr values obtamed m different studies it is recommended to
use pooled noimal plasma contaming samples from a large number of
volunteers (to mimmize vanations m the percentage ot carners of
factor VLeidcn) and to exclude women who use oral contraceptives
nAPCsr obtamed with the thrombin generation-based APC
resistance test are hardly affected by the handlmg of plasma The major
variable to control appears to be the concentration of anticoagulant
(Tables 3, 4) This is not surpnsmg considermg the CaCl2 dependence
of the measurement m the presence of APC (cf Fig 2) and the fact that
the normal plasma pool used for normahzalion was collected at 3 8%
An influence of anticoagulant concentration has also been repoited for
coagulation tests (cg INR) that are based on measurement on the
clottmg of plasma mitiated with tissue factoi (35) Therefore, it is
piefeiable to normahze APCsr agamst a pooled normal plasma that
is collected on the same concentration of anticoagulant The linear
regression analysis further mdicated a small influence of the storage
time of blood before plasma is prepared (Table 4) Other variables
appeared to have httle or no influence
We feel that the data presented in this paper will allow other
laboratones to implement the thrombin generation based APC
resistance measuiement but it will be clear that stnct attention has to be
given to standardization not only of assay conditions but also of the way
plasmas and normal pools are prepared in order to pave the way for a
larger mter laboratory study m the future
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